Exagen, Inc. (XGN)
7.74
-0.82
(-9.58%)
USD |
NASDAQ |
Oct 16, 13:09
Exagen SG&A Expense (TTM) : 48.45M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.45M |
| March 31, 2026 | 47.48M |
| December 31, 2025 | 46.62M |
| September 30, 2025 | 44.40M |
| June 30, 2025 | 43.11M |
| March 31, 2025 | 42.04M |
| December 31, 2024 | 41.37M |
| September 30, 2024 | 43.38M |
| June 30, 2024 | 44.60M |
| March 31, 2024 | 46.09M |
| December 31, 2023 | 47.43M |
| September 30, 2023 | 48.02M |
| June 30, 2023 | 50.80M |
| March 31, 2023 | 51.75M |
| December 31, 2022 | 52.02M |
| September 30, 2022 | 51.01M |
| June 30, 2022 | 48.38M |
| March 31, 2022 | 46.65M |
| December 31, 2021 | 44.54M |
| September 30, 2021 | 42.67M |
| June 30, 2021 | 40.34M |
| March 31, 2021 | 37.45M |
| December 31, 2020 | 37.03M |
| Date | Value |
|---|---|
| September 30, 2020 | 35.02M |
| June 30, 2020 | 33.12M |
| March 31, 2020 | 32.15M |
| December 31, 2019 | 28.70M |
| September 30, 2019 | 20.79M |
| June 30, 2019 | 18.41M |
| March 31, 2019 | 15.90M |
| December 31, 2018 | 14.42M |
| September 30, 2018 | 18.75M |
| June 30, 2018 | 18.12M |
| March 31, 2018 | 17.87M |
| December 31, 2015 | 17.41M |
| September 30, 2015 | 17.33M |
| June 30, 2015 | 17.10M |
| March 31, 2015 | 16.28M |
| December 31, 2014 | 15.07M |
| September 30, 2014 | 13.08M |
| June 30, 2014 | 10.70M |
| March 31, 2014 | 8.543M |
| December 31, 2013 | 6.993M |
| September 30, 2013 | 4.725M |
| June 30, 2013 | 3.031M |
| March 31, 2013 | 1.47M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Myriad Genetics, Inc. | 539.90M |
| BioRestorative Therapies, Inc. | 5.181M |
| CareDx, Inc. | 247.69M |
| Natera, Inc. | 1.255B |
| Sera Prognostics, Inc. | 24.17M |